Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen

Bruce E. Bejcek, Duo Wang, Erica Berven, Christopher A. Pennell, Stephen C. Peiper, Sibrand Poppema, Fatih M. Uckun, John H. Kersey

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Antibodies that recognize antigens restricted to leukemia, lymphoma, and normal hematopoietic cells represent a unique opportunity to develop therapeutics, because they have the potential for relatively selective treatment of these diseases. Antibodies that recognize the CD19 antigen found on normal and malignant B cells, but not on stem cells, have been used to develop immunoconjugates. However, these conjugates are large and might be suboptimal in tumor penetration when compared to molecules using smaller single chain Fv (scFv) antibody fragments. scFv has the advantage of being a molecularly engineered homogeneous molecule. In this report, we demonstrate the cloning, expression, and binding of three anti-CD19 antibodies as scFvs. All three scFvs were successfully cloned and expressed. FVS191, derived from ceU line B43, and FVS192, derived from SJ25C1, were properly refolded and bound CD19 antigen in FACS competition assays. These anti-CD19 scFv should be useful in the further development of diagnostic and therapeutic molecules.

Original languageEnglish (US)
Pages (from-to)2346-2351
Number of pages6
JournalCancer Research
Volume55
Issue number11
StatePublished - Jun 1 1995

Fingerprint Dive into the research topics of 'Development and Characterization of Three Recombinant Single Chain Antibody Fragments (scFvs) Directed against the CD19 Antigen'. Together they form a unique fingerprint.

Cite this